Author Intervention Numbers Result
Robertson et al [26] Intermittent ML vs. placebo 220 Intermittent ML superior to placebo
Bacharier et al [27] Intermittent ML vs. intermittent nebulised BUD vs. placebo 238 Intermittent ML and nebulized BUD equivalent and better than placebo
Valovirta et al [28] Intermittent ML vs. continuous ML vs. placebo 1771 No benefit of either ML regime
Nwokoro et al [29]
Intermittent ML vs. placebo Sub analysis by ALOX5 promoter polymorphisms
1346
No benefit of ML Possible benefit of ALOX5 promoter genotyping